This report examines the legislative and regulatory landscape surrounding the phase-out of chlorofluorocarbon (CFC)-based metered dose inhalers (MDIs). It details the scientific basis for the phase-out, focusing on the environmental impact of CFCs and the subsequent development of alternative propellant technologies. The document outlines the governmental efforts, primarily from the U.S. Congress's House Committee on Commerce, Subcommittee on Health and the Environment, to manage this transition and ensure patient access to necessary respiratory treatments.

This document serves as a record of a specific legislative and regulatory moment concerning public health and environmental policy. Its value lies in its detailed account of governmental deliberations and the scientific rationale behind the mandated shift away from CFC propellants in medical devices. The report is a primary source for understanding the policy-making process during a critical period of environmental regulation.